Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Immunomedics

This article was originally published in The Gray Sheet

Executive Summary

Immunomedics: Initiates Phase III clinical trials for LymphoScan, a nuclear imaging product for the detection of lymphoma, the firm announces July 24. The trials, which will involve approximately 250 patients at over 20 U.S. and European sites, will determine the device's ability to detect the presence, location and extent of non-Hodgkin's lymphomas, and its capability to distinguish residual disease from non-malignant fibrosis in patients undergoing drug or radiation therapy. In Phase II trials, LymphoScan demonstrated 86% sensitivity for lymphoma detection and 100% positive predictive rate for the presence of disease in 43 patients, the Morris Plains, New Jersey firm claims...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT006431

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel